We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has hit Mesoblast’s biologics license application (BLA) for Ryoncil (remestemcel-L) with a complete response letter despite a strong vote by the agency’s expert advisory committee vote in favor of the stem cell treatment for pediatric steroid-refractory acute graft vs. host disease. Read More
AbbVie is currently developing the investigational antibody for the treatment of spinal cord injuries, multiple sclerosis and acute ischemic stroke. Read More